-
An Expected Failure From Karyopharm's Selinexor Doesn't Change The Bull Thesis
Friday, March 3, 2017 - 9:27am | 414Read More...Karyopharm Therapeutics Inc (NASDAQ: KPTI) announced that the interim analysis of its Phase 2 SOPRA study of selinexor monotherapy in acute myelogenous leukemia (AML) failed to meet the primary endpoint of overall survival (OS). Wedbush’s David M. Nierengarten maintaisd an Outperform rating...
